Last reviewed · How we verify
Vemurafenib in combination with cobimetinib — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Vemurafenib in combination with cobimetinib (Vemurafenib in combination with cobimetinib) — Cancer Research UK.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Vemurafenib in combination with cobimetinib TARGET | Vemurafenib in combination with cobimetinib | Cancer Research UK | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Vemurafenib in combination with cobimetinib CI watch — RSS
- Vemurafenib in combination with cobimetinib CI watch — Atom
- Vemurafenib in combination with cobimetinib CI watch — JSON
- Vemurafenib in combination with cobimetinib alone — RSS
Cite this brief
Drug Landscape (2026). Vemurafenib in combination with cobimetinib — Competitive Intelligence Brief. https://druglandscape.com/ci/vemurafenib-in-combination-with-cobimetinib. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab